MEI Pharma Inc
0.00 (0.00%)


Draw Mode:

Volume 100
Bid Price 0.237
Ask Price 0.2645
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
MEI Pharma Inc MEIP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.2501 05:05:01
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
1 100 - 0.20 - 1.87
Last Trade Time Type Quantity Stock Price Currency
04:50:05 formt 100 $ 0.2501 USD

MEI Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 33.33M 133.26M 132.64M $ 52.72M $ -28.36M -0.51 37.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 0.60%

more financials information »

MEI Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No MEIP Message Board. Create One! See More Posts on MEIP Message Board See More Message Board Posts

Historical MEIP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.24660.25610.23160.24615411,122,4830.00351.42%
1 Month0.2990.32980.200.23466452,026,549-0.0489-16.35%
3 Months0.23820.350.200.26010641,144,8160.01195.0%
6 Months0.420.440.200.29117181,201,928-0.1699-40.45%
1 Year1.801.870.200.51700132,880,870-1.55-86.11%
3 Years1.064.5750.201.591,700,038-0.8099-76.41%
5 Years2.17995.140.201.731,163,929-1.93-88.53%

MEI Pharma Description

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.